Arcus Biosciences Halts Late-Stage Trial of Anti-TIGIT Therapy in Collaboration with Gilead Sciences
Arcus Biosciences (RCUS) saw its stock decline in premarket trading after halting a late-stage trial of its anti-TIGIT therapy domvanalimab in lung cancer, which was part of a collaboration with Gilead Sciences. The decision may raise concerns about the drug's efficacy or safety, potentially impacting investor confidence in the company's pipeline.
Topics: Arcus Biosciences biotech clinical trials drug development Gilead Sciences